Heart MRI blood flow scans to tell apart thick heart muscle diseases
Compares heart blood flow on MRI in hypertrophic cardiomyopathy, Fabry disease and amyloidosis.
Key facts
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Where
- Bologna, ItalySee the site
- Trial code
- Registry title
- Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
- Status
- Recruiting
- People taking part
- 250 people, planned
- Started
- 1 Jun 2025
- Expected to end
- 1 Jun 2027
- Type of study
- Observational
- Record updated
- 2 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a heart muscle disease that thickens the heart wall (hypertrophic cardiomyopathy), their close relatives, and people who carry a gene change for it. They need a heart MRI scan.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Confirmed cardiomyopathy with a thickened heart muscle (hypertrophic phenotype), per current ESC guidelines; or a first-degree relative of such a patient; or a carrier of a hypertrophic cardiomyopathy gene change.
- Earlier treatment
- No previous heart attack and no previous heart revascularization (bypass surgery or coronary angioplasty).
- Biomarker or test result
- Carriers of a genetic mutation for hypertrophic cardiomyopathy can join. No specific test result is required for the others.
Main reasons for not taking part
- Previous heart attack (myocardial infarction)
- Previous coronary bypass surgery or coronary angioplasty
- Coronary stenosis of 50% or more on coronary CT scan or invasive coronary angiography
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- A confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype, according to current ESC guidelines; or a first-degree relative of a patient with a confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype; or a carrier of a genetic mutation for hypertrophic cardiomyopathy (carriers)
- Patient with an indication to undergo cardiac magnetic resonance imaging (CMR) according to current ESC guidelines
- Age ≥ 18 years
- Written informed consent obtained
Who cannot take part
- History of previous myocardial infarction or myocardial revascularization (coronary artery bypass grafting or percutaneous coronary angioplasty) and/or evidence of coronary stenosis ≥ 50% on coronary CT scan or invasive coronary angiography
Where in Italy
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyContact: Luigi LovatoTaking people
About the trial
What the trial wants to find out
This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease (AFD), and cardiac amyloidosis. The study will also include first-degree relatives of affected patients and genetic mutation carriers. By comparing myocardial blood flow and perfusion patterns across these different conditions, the study seeks to identify distinctive perfusion signatures that may improve diagnostic differentiation, support risk stratification, and provide insights into the role of ischemia in fibrosis progression, arrhythmias, and long-term outcomes.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
- Plain-language title
- Heart MRI blood flow scans to tell apart thick heart muscle diseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 February 2026